ADNP Syndrome: Causes, Symptoms, and Diagnosis

ADNP syndrome, also called Helsmoortel–Van der Aa syndrome, is a rare genetic neurodevelopmental condition caused by mutations in the ADNP gene on chromosome 20. Children with this syndrome typically present with intellectual disability, autism spectrum features, delayed motor milestones, and distinctive physical traits. Because the condition was only formally described in 2014, awareness among clinicians is still catching up, and many families spend years searching for answers before receiving a diagnosis through genetic testing.

What the ADNP Gene Does and How Mutations Disrupt It

The ADNP gene encodes a protein that plays a central role in brain development and ongoing neural function. During early brain formation, the ADNP protein works with a partner called Chd4 as part of a larger molecular complex. Together, they regulate genes involved in cortical growth and the structural packaging of DNA in developing neurons.¹ When one copy of the ADNP gene carries a harmful mutation, the protein it produces is truncated or nonfunctional, and the remaining healthy copy cannot fully compensate. Nearly all cases arise from new (de novo) mutations, meaning the child’s parents do not carry the mutation themselves.

Beyond its role in gene regulation, the ADNP protein interacts directly with the cell’s internal scaffolding, called microtubules, through a small segment of the protein known as NAP. In animal models, losing one working copy of ADNP leads to problems with microtubule stability, disrupted transport of cargo along nerve cell extensions, and buildup of abnormal tau protein tangles similar to what is seen in neurodegenerative diseases.² This combination of disrupted gene regulation and compromised cellular infrastructure explains why the syndrome affects so many different body systems.

Recent research has also uncovered that ADNP itself can act as a methyltransferase, an enzyme that chemically tags DNA and proteins to influence which genes get turned on or off. When researchers tested mutated versions of ADNP, most showed reduced tagging activity, consistent with a loss of function. However, mutations clustered near a specific part of the protein called the nuclear localization signal showed an unusual pattern of increased tagging, suggesting those particular mutations may cause harm through a different, gain-of-function mechanism.³

Two Molecular Subtypes Within One Syndrome

One of the most striking findings in ADNP research is that not all mutations produce the same molecular fingerprint. Researchers analyzing blood samples from 22 patients identified two distinct patterns of DNA methylation changes. The first pattern, called epi-ADNP-1, involved roughly 6,000 DNA sites that were mostly under-tagged. The second, epi-ADNP-2, involved about 1,000 sites that were predominantly over-tagged. These patterns mapped to where the mutation sat within the gene: mutations near the ends of the protein correlated with epi-ADNP-1, while mutations near the nuclear localization signal in the middle correlated with epi-ADNP-2.⁴ A broader study of methylation signatures across dozens of neurodevelopmental conditions confirmed that ADNP was the only gene in which mutations produced two distinguishable molecular subtypes.⁵

This dual-signature finding matters clinically because the two subtypes appear to produce somewhat different symptom profiles. Mutations near the nuclear localization signal have been particularly associated with disrupted acquisition of motor behaviors.⁶ Meanwhile, an autopsy study of brain tissue from a patient with ADNP syndrome confirmed that the epi-ADNP-1 methylation pattern seen in blood also appears in the cerebellum, with disrupted expression of genes involved in brain development, cytoskeletal structure, and cellular recycling processes.⁷

How Severity Varies by Mutation

Within the spectrum of ADNP mutations, one recurrent variant stands out. The p.Tyr719* mutation, which truncates the protein at the same position in multiple unrelated patients, has been associated with more severe outcomes across the board compared with other ADNP mutations.⁸ Animal modeling of this specific mutation has shown that it leads to early tau accumulation in the brain, and when mice carrying it were exposed to disrupted light-dark cycles, a striking proportion lost detectable circadian rhythmicity entirely, with males being especially vulnerable.⁹

More generally, the length of the remaining mutated protein appears to predict communication ability. In a longitudinal study of 15 patients, shorter truncated proteins correlated with worse communication skills, and this correlation was especially pronounced in males.⁶ That same study found that developmental delays appeared to compound over time, supporting a picture of both slowed development and features of accelerated aging, a combination that underscores why early intervention matters.

The Symptom Landscape

ADNP syndrome affects multiple body systems, and its presentation can vary considerably from child to child. That said, certain features appear in the vast majority of affected individuals.

Intellectual disability is universal. In a study of 11 individuals evaluated with standardized cognitive testing, all had moderate to profound intellectual impairment, and roughly two-thirds met formal diagnostic criteria for autism spectrum disorder.¹⁰ Speech is typically the most affected domain. Many children are minimally verbal or nonverbal and rely on augmentative communication tools. Those who do develop some spoken language tend to have significant delays. Motor development is also broadly delayed: most children sit, crawl, and walk later than expected, and some never achieve independent walking.

A qualitative study drawing on caregiver reports highlighted a range of additional medical issues. Chronic constipation was one of the most commonly reported gastrointestinal problems. Several children had congenital heart defects, including ventricular septal defects, and some had been diagnosed with hypothyroidism. Recurrent infections were noted in a subset, possibly related to oral sensory-seeking behavior that increases germ exposure.¹¹

Vision problems also appear to be part of the syndrome. One detailed ophthalmological case report documented progressive nystagmus (involuntary eye movements), underdeveloped structures in the center of the retina, and worsening cone cell function over time.¹² While a single case report cannot establish prevalence, clinicians familiar with the syndrome generally recommend early and ongoing eye exams.

Sleep Disruption and Circadian Problems

Sleep difficulties are a common and often exhausting feature of ADNP syndrome for families. In a comparison of sleep patterns across several genetic subtypes of autism, children with ADNP mutations showed more overall sleep problems than children with mutations in other genes like CHD8 or DYRK1A.¹³ Parents frequently describe difficulty with both falling asleep and staying asleep, nighttime waking, and irregular sleep-wake patterns.

The biological basis for these sleep issues likely involves the circadian clock itself. Mouse studies have demonstrated that ADNP mutations disrupt the organization of circadian rhythms, with the nature of the disruption differing by sex: male mice showed broadly reduced activity and weakened rhythmic output, while female mice showed shifted timing and more fragmented activity patterns.⁹ This sex difference in circadian vulnerability echoes a broader pattern seen across ADNP research: the syndrome tends to affect males and females somewhat differently across multiple domains, including muscle gene regulation and motor behavior.¹⁴

Early Teething as a Diagnostic Clue

One of the more unexpected findings in ADNP syndrome is unusually early tooth eruption. In a survey of 54 families, about 81% of children with ADNP mutations had nearly a full set of baby teeth, including molars, by their first birthday. In contrast, none of 18 healthy siblings showed early teething.¹⁵ In typical development, molars do not usually appear until 13 to 19 months at the earliest, so having them by 12 months is a noticeable departure. Some parents reported multiple teeth erupting simultaneously.

This finding has practical value because early teething is visible long before genetic test results come back, and it is easy for a pediatrician or dentist to notice. When a baby presents with global developmental delays, features of autism, and a surprisingly full mouth of teeth before age one, ADNP syndrome should be on the differential diagnosis list. The researchers who described this pattern proposed premature tooth eruption as a potential early biomarker that could prompt clinicians to order genetic testing sooner.

How ADNP Syndrome Is Diagnosed

The gold standard for confirming ADNP syndrome is genetic testing, most often through whole-exome sequencing or a targeted gene panel that includes ADNP. Because the mutations are almost always de novo, family history is typically unremarkable, which means the clinical picture alone has to raise suspicion. In at least one reported case, abnormal findings on a prenatal ultrasound led to sequencing of amniotic fluid cells, which revealed a de novo ADNP mutation and allowed diagnosis before birth.¹⁶

The DNA methylation episignatures described earlier are also emerging as a diagnostic tool. When standard sequencing finds a variant of uncertain significance in the ADNP gene, testing the patient’s blood for the characteristic epi-ADNP-1 or epi-ADNP-2 methylation pattern can confirm whether the variant is truly pathogenic.⁴ This approach is especially useful because a significant fraction of the mutations found through sequencing are novel, meaning they have never been seen before in another patient, and their pathogenicity can be difficult to assess from the DNA change alone. Having a functional readout in the form of a methylation profile adds a second line of evidence.

Despite these advances, many children with ADNP syndrome still receive their diagnosis years into life, often after an exhausting odyssey of specialist visits and inconclusive tests. A clinical review emphasized that early diagnosis enables earlier access to tailored therapy and monitoring for the syndrome’s known medical complications, including cardiac, endocrine, and ophthalmological issues.¹⁷

What Happens Over Time

One of the harder realities of ADNP syndrome is that the developmental gap between affected individuals and their peers tends to widen with age rather than narrow. A study tracking adaptive behavior scores in both children and adults with the syndrome found that adults scored at the lowest measurable levels across all domains. When researchers compared childhood and adult scores, the trajectory pointed to a continuous decline relative to the general population, suggesting both slowed development and possible neurodegenerative processes.¹⁸

The neurodegenerative angle is supported by the tau pathology seen in animal models. Mice missing one copy of ADNP develop tangle-like structures in the brain as they age, and cognitive function declines in parallel.² Whether this maps directly onto what happens in human patients over decades is not yet clear, but it gives urgency to the search for treatments that could slow or prevent the degenerative component.

Therapeutic Research

No approved disease-modifying treatment for ADNP syndrome currently exists, but two investigational approaches have generated attention in the research community.

The most advanced candidate is davunetide (also called NAP), a small peptide derived from the ADNP protein itself. The idea behind it is elegant: since many of the syndrome’s problems stem from the loss of functional ADNP activity on microtubules, delivering the active fragment of the protein could compensate for what the mutation takes away. In preclinical models, NAP stabilizes microtubules, improves cognitive performance, and corrects behavioral deficits. Delivered intranasally, it reaches the brain with favorable bioavailability and has demonstrated a reassuring safety profile in clinical studies.¹⁹ Laboratory work has further shown that NAP enters both the cytoplasm and the nucleus of cells, helping to explain how it could address multiple aspects of ADNP dysfunction rather than just the microtubule problems.²⁰ While davunetide has not yet been tested in a large trial specifically in children with ADNP syndrome, its earlier testing in progressive supranuclear palsy (another tauopathy) showed that it significantly slowed disease progression in women, offering some basis for cautious optimism.

A separate approach explored low-dose ketamine in 10 children with ADNP syndrome through an open-label study. Ketamine was generally well tolerated; the most common side effects were silliness, drowsiness, and decreased appetite. After one week of treatment, caregiver ratings showed improvement across a wide range of domains, including social behavior, attention, repetitive behaviors, and sensory reactivity. Clinician-rated scales also reflected global improvement.²¹ Because the study was small and lacked a placebo group, these results are best interpreted as signal-finding rather than proof of efficacy, but they have opened a new line of inquiry.

Sex Differences Across the Syndrome

A thread running through much of the ADNP research is that the syndrome does not behave identically in males and females. The genotype-phenotype study linking protein length to communication skills found that the correlation was more pronounced in boys.⁶ Circadian disruption in mice diverged sharply by sex, with males losing overall activity and females showing shifted timing and fragmented patterns.⁹ And the ADNP protein’s regulation of muscle gene expression shows age-dependent and sex-dependent patterns in mice.¹⁴ Even at the epigenetic level, the methyltransferase work revealed a male-specific reduction in a particular histone modification in the cerebellum.³

The clinical significance of these sex differences is still being worked out. For families, it may eventually mean that boys and girls with ADNP syndrome benefit from somewhat different monitoring strategies and therapeutic priorities. For researchers, it complicates study design: pooling male and female data without accounting for sex could mask real treatment effects or produce misleading averages. This is an area where the science is genuinely still in motion, and results from the next generation of clinical studies may reshape current assumptions considerably.

What Families Encounter Day to Day

The medical literature captures the syndrome’s features as checklists of symptoms, but for families the lived experience is far messier. Feeding difficulties are a constant challenge for many children in the early years, partly because of gastrointestinal issues and partly because of sensory sensitivities that make certain textures intolerable. Behavioral features such as hand flapping, mouthing of objects, and a high pain threshold are commonly described by caregivers and can create safety concerns. Most children require intensive daily support with occupational therapy, speech therapy, and physical therapy, often beginning in infancy and continuing indefinitely.

The qualitative caregiver study highlighted that families also contend with the frustration of medical professionals who have never heard of the syndrome. Because ADNP syndrome is estimated to account for a small but meaningful fraction of all syndromic autism cases, general pediatricians may encounter only one affected child in a career.¹¹ Parent-driven organizations have played an outsized role in connecting families, coordinating research participation, and pushing for clinical trials. For a rare disease with no approved treatment, the community itself often functions as the most reliable source of practical guidance on day-to-day management.